Bakris on Nephrology

 
 

  • Dosing at Night to Cause BP 'Dipping'   Prescribing short-term blood pressure medication could help patients achieve 'dips' overnight and reduce their risk for cardiovascular events, reports Dr George Bakris.
  • Systolic Over 160? Start Combo Therapy Upfront   Dr George Bakris explains why combination therapy in a single-pill form is the standard of care for patients with stage 2 hypertension and systolic blood pressure of 160 and above.
  • In Advanced CKD, Thiazide May Help Control BP   Dr. George Bakris interviews Dr. Rajiv Agarwal about a small study that could redeem chlorthalidone's role in controlling blood pressure in patients with moderate to advanced chronic kidney disease.
  • Beta-Blockers Beat ACE Inhibitors in Dialysis Patients   Dr. George Bakris talks with Dr. Rajiv Agarwal about new research comparing the effectiveness of beta-blockers vs ACE inhibitors at controlling blood pressure in patients on dialysis.
  • The SYMPLICITY HTN-3 Co-PI Gives His 2 Cents Co-PI Dr. George Bakris shares his perspective on what went wrong with the SYMPLICITY HTN-3 trial, and where it leaves renal denervation.
  • Stroke Risk in Patients With CKD: What Do We Know?   CKD patients are at higher risk for stroke. Drs. Bakris and Gorelick discuss the factors that contribute to this risk and the still unanswered questions.
  • Hemoglobin or Epo Dose: Which Poses Heart Risk?   George Bakris talked to Peter McCullough about the role of hemoglobin and erythropoietin in cardiovascular events in patients with chronic kidney disease.
  • Pulmonary Hypertension in Kidney Disease: An Expert Perspective   George Bakris talks to Bisher Kawar about an important review of pulmonary hypertension in renal disease -- a serious and under-recognized problem in patients in with kidney disease.
  • Microalbuminuria: Is It Even a Word Anymore?   Dr. George Bakris Skypes with Dr. Richard Glassock about microalbuminuria, and whether it's a risk factor or a marker.
  • CKD and Heart Disease: It's a Factor -- Not a Marker   George Bakris talks to Paul Muntner via Skype about chronic kidney disease as a factor -- not a marker -- in cardiovascular disease.
  • Rising Creatinine With RAS Inhibitors: Should We Worry?   George Bakris, MD, talks to Sheldon Hirsch, MD, about a new study that addressed the issue of rising creatinine levels in patients with CKD who are taking RAS blockers.
  • Progressing to ESRD: Are All BP Goals the Same?   George Bakris talks to Carmen Peralta about a key study that uses KEEP screening data to identify blood pressure levels in kidney disease that lead to progression to ESRD.
  • Managing the Non-Dippers: Possible? Worth It?   George Bakris, MD, talks to Mahboob Rahman, MD, about nocturnal blood pressure and whether it is possible to convert non-dipping patients to dipping status.
  • For Low BP: Sleep Slow and Deep   George Bakris talks to Susan Redline about a study in Hypertension finding an association between slow-wave sleep and lower blood pressure.
  • Renal Denervation and SYMPLICITY HTN-3: What to Expect   George Bakris, MD, talks to Raymond R. Townsend, MD, about renal denervation, SIMPLICITY-3, and the definitions of resistant and refractory hypertension.
  • Bardoxolone and Diabetic Nephropathy   George Bakris talks to Robert Toto about the BEACON trial, which will study bardoxolone, a drug with many promising effects in patients with diabetes and nephropathy.
  • The Right Antihypertensives at the Best Price   George Bakris, MD, talks to Rajiv Agarwal, MD, via Skype about the evidence behind the new recommendations in the NICE guidelines for combination therapy in hypertension and which ones are cost effective.
  • Blood Pressure Goals: Is 140 Good Enough for Everyone?   George Bakris, MD, Skypes with Rajiv Agarwal, MD, about blood pressure goals in the NICE guidelines and whether anyone needs to aim as low as 130/80 mm Hg.
  • The NICE Hypertension Guidelines: A Monitoring Revolution   George Bakris, MD, talks to Rajiv Agarwal, MD, via Skype about the NICE hypertension guidelines and the critical practice-changing components.